Rectify Pharmaceuticals

Rectify Pharma is a biotech startup that specializes in the development of small molecule therapies. These therapies are designed to restore and enhance the function of ATP-binding cassette (ABC) transporters, a type of protein that plays a crucial role in the body by transporting various substances across cell membranes. The company's innovative product platform is aimed at discovering new treatments for a variety of diseases, including those affecting the liver, biliary system, eyes, central nervous system, and cardiometabolic health.

Rectify Pharma's primary market is the healthcare sector, specifically targeting both rare and common diseases. Their business model revolves around the research and development of first-in-class therapies, which they aim to commercialize through partnerships or sales to larger pharmaceutical companies.

The company is led by Rajesh Devraj, Ph.D., a seasoned biotech executive with a track record of building successful companies. His extensive experience in the field, coupled with a strong leadership team, positions Rectify Pharma well for future growth and innovation.

In summary, Rectify Pharma is a promising biotech startup that leverages cutting-edge science to develop novel therapies for a range of diseases. Their focus on ABC transporter function could potentially open up new avenues for treatment, making them a company to watch in the healthcare sector.

Keywords: Biotech, Small Molecule Therapies, ATP-Binding Cassette Transporters, Healthcare, Rare Diseases, Common Diseases, Research and Development, Commercialization, Leadership, Innovation.